Biosergen publishes interim report for first quarter 2022
Tuesday, May 31, 2022: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the firdst quarter 2022. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q1 2022
| Amounts in SEK '000 | Q1 2022 | Q1 2021 | Year 2021 |
| Consolidated group revenue | 1,317 | 0 | 11,570 |
| Consolidated group loss before depreciation | -5,018 | -8,305 | -34,077 |
| Consolidated group loss before net financials | - 5,018 | -8,305 | -34,077 |
| Consolidated net result | -5,015 | -8,305 | -34,318 |
| Consolidated earnings per share (EPS) | -0,18 | 0 | -1,22 |
Highlights during Q1 2022
There were no highlights during the period
Highlights after the period
- April 7, The first subject has been dosed in the phase 1 trial of BSG005
- May 13, Biosergen successfully completes first cohort of BSG005 phase 1 trial
The Financial report can be found on our website: https://biosergen.net/investors/filings
For further information about Biosergen, please contact:
Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net
Certified Adviser
Erik Penser Bank
Telefon: +46 8 463 8000
E-mail: certifiedadvisor@penser.se
This information is such information that Biosergen AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on May 31, 2022.
ABOUT BIOSERGEN
Biosergen is a clinical stage biotechnology company that employs all its organizational and financial resources on the clinical development of BSG005. BSG005, a polyene macrolide, is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, and being completely free of the kidney toxicity hampering other drugs in its class. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care. The Company is also developing BSG005 Nano where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal infection. BSG005 Nano Oral is an extension of BSG005 Nano. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen is granted orphan drug status for BSG005 in the United States.